Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by PresidentBidenon Mar 02, 2021 8:56am
149 Views
Post# 32693264

From KLY financials September 30th, 2020

From KLY financials September 30th, 2020

On October 30, 2019, the Company also announced it had entered into an agreement to amend the terms of the convertible debenture units issued to a single investor in a private placement on March 6, 2019. The convertible debenture units consist of CAD$787.5 thousands principal amount of 10.0% secured convertible debenture (the “Convertible Debenture”) maturing on March 6, 2021 and 12,115,384 Common share purchase warrants (the “Debenture Warrants”) initially expiring on March 6, 2021. Under the amendments, the conversion price of the Convertible Debenture (for the first 12 months following the issuance date) and the exercise price of the Debenture Warrants was reduced to CAD$0.05 from CAD$0.065.


<< Previous
Bullboard Posts
Next >>